All In Biotech

Drug Trial Radar · NCT07632274

A Study to Evaluate Ibuprofen (IBU) 62.5 mg and Acetaminophen (APAP) 125 mg/5 ml in an Oral Liquid Suspension Fixed-Dose Combination Product in Children Aged 6 to 11 Years

A Phase I, Single-Center, Open-Label, Single-Dose, Pharmacokinetic Study to Evaluate Ibuprofen (IBU) 62.5 mg and Acetaminophen (APAP) 125 mg/5 ml in an Oral Liquid Suspension Fixed-Dose Combination Product in Children Aged 6 to 11 Years

Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Jun 19, 2026

Primary completion

Sep 2026

Study completion Sep 2026

Sponsor

Lead sponsor
HALEONIndustry
Sponsor type
Industry
First posted
Jun 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 11 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study will be to characterize the pharmacokinetic (PK) profile of the Fixed-Dose Combination (FDC) IBU 62.5 milligram (mg)/APAP 125 mg per 5 milliliter (mL) suspension in children 6 to 11 years of age, inclusive, to satisfy Pediatric Research Equity Act (PREA) requirements.

Conditions

  • Pain

Interventions

  • Test ProductDrug

    Liquid suspension FDC IBU 62.5 mg / APAP 125 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Plasma Concentration Versus (Vs.) Time Curve Calculated from Time 0 to the Last Measurable Sampling Time Point (AUC0-t) for Ibuprofen and AcetaminophenTime frame: Pre-dose (within 1 hour prior to dosing) and at 5, 15, 30 minutes and 1 ,1.25, 1.5, 2, 4, 6, 9, 12 hours post dose on Day 1
  2. Area Under the Plasma Concentration Vs. Time Curve Calculated from Time 0 To Infinity (AUC0-inf) for Ibuprofen and AcetaminophenTime frame: Pre-dose (within 1 hour prior to dosing) and at 5, 15, 30 minutes and 1, 1.25, 1.5, 2, 4, 6, 9, 12 hours post dose on Day 1
  3. Peak or Maximum Observed Plasma Concentration (Cmax) for Ibuprofen and AcetaminophenTime frame: Pre-dose (within 1 hour prior to dosing) and at 5, 15, 30 minutes and 1, 1.25, 1.5, 2, 4, 6, 9, 12 hours post dose on Day 1
  4. Time to Reach Maximum Plasma Concentration (Tmax) for Ibuprofen and AcetaminophenTime frame: Pre-dose (within 1 hour prior to dosing) and at 5, 15, 30 minutes and 1, 1.25, 1.5, 2, 4, 6, 9, 12 hours post dose on Day 1
  5. Apparent Terminal Elimination Rate Constant (λz) for Ibuprofen and AcetaminophenTime frame: Pre-dose (within 1 hour prior to dosing) and at 5, 15, 30 minutes and 1, 1.25, 1.5, 2, 4, 6, 9, 12 hours post dose on Day 1
  6. Terminal Half-Life (t1/2) for Ibuprofen and AcetaminophenTime frame: Pre-dose (within 1 hour prior to dosing) and at 5, 15, 30 minutes and 1, 1.25, 1.5, 2, 4, 6, 9, 12 hours post dose on Day 1
  7. Apparent Volume of Distribution (Vz/F) for Ibuprofen and AcetaminophenTime frame: Pre-dose (within 1 hour prior to dosing) and at 5, 15, 30 minutes and 1, 1.25, 1.5, 2, 4, 6, 9, 12 hours post dose on Day 1
  8. Apparent Total Clearance (Cl/F) for Ibuprofen and AcetaminophenTime frame: Pre-dose (within 1 hour prior to dosing) and at 5, 15, 30 minutes and 1, 1.25, 1.5, 2, 4, 6, 9, 12 hours post dose on Day 1
  9. Apparent Volume of Distribution, Adjusted for Body Size (Vz/F/lbs) for Ibuprofen and AcetaminophenTime frame: Pre-dose (within 1 hour prior to dosing) and at 5, 15, 30 minutes and 1, 1.25, 1.5, 2, 4, 6, 9, 12 hours post dose on Day 1
  10. Apparent Total Clearance, Adjusted for Body Size (Cl/F/lbs) for Ibuprofen and AcetaminophenTime frame: Pre-dose (within 1 hour prior to dosing) and at 5, 15, 30 minutes and 1, 1.25, 1.5, 2, 4, 6, 9, 12 hours post dose on Day 1

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CenExel Salt Lake

    Salt Lake City, Utah · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.